Detecting pulmonary malignancy against benign nodules using noninvasive cell-free DNA fragmentomics assay
Source check: Source checked. Not independent scientific confirmation.
Finding: A cfDNA fragmentomics AutoML ensemble distinguished malignant from benign nodules among patients with suspicious LDCT findings (AUC 0.857 in the independent validation cohort and 0.860 in a separate 99-patient test cohort). The AACR 2023 abstract reports the same result; this supports a diagnostic signal in selected, pathologically assessed patients, not mortality reduction or population-screening benefit.
Technology: AutoML tunes a stacked cfDNA-fragmentomics model to classify suspicious lung nodules as malignant or benign.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- AutoML tunes a stacked cfDNA-fragmentomics model to classify suspicious lung nodules as malignant or benign.
- Test and result
- Among LDCT-suspicious patients, the ensemble distinguished pathologically classified malignant and benign nodules; validation AUC 0.857 and separate external-test AUC 0.860.
- Limitation / still unknown
- Training and validation cohorts were separated 237/118 patients and a separate 99-patient test cohort was reported; nodule status was pathologically confirmed. Sensitivity/specificity evidence does not establish improved outcomes or performance in unselected screening populations.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11345357/ · https://europepmc.org/article/MED/39088983 · https://doi.org/10.1158/1538-7445.AM2023-5394 · https://pubmed.ncbi.nlm.nih.gov/39088983/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.